Nexium Control formulation

Nexium Control contains esomeprazole

Esomeprazole is a proton pump inhibitor (PPI) and works by blocking the proton pump in parietal cells (cells lining the stomach). This reduces the amount of acid in the stomach, whilst leaving enough acid to digest food. Learn more about heartburn.

Learn more

Antacids and alginates may only provide short acting relief

Antacids react with gastric acid, neutralising it.

Alginates form a temporary physical barrier (or raft) on top of the stomach helping to prevent the contents from escaping through the sphincter. Their effectiveness depends on the stomach contents, with them being less effective if taken during a meal or when lying down.

For both antacids and alginates, once the stomach empties, their effects cease. Repeated dosing is necessary to provide relief from newly secreted acid.

This need for repeat dosing can lead to patients developing a ‘burn-suffer-treat' reactive cycle which may not provide the sustained relief from frequent heartburn that they need.

Image of Nexium Control breaking the cycle of heartburn

Nexium Control provides long-lasting relief

Nexium Control, with esomeprazole, reduces the production of stomach acid for 24-hour protection, treating the cause and symptoms of heartburn. Allowing time for the oesophagus to recover from the acid irritation.

Protection is achieved with the convenience of once a day dosing*.

*Some people experience relief within a day, though for some, it may take 2 – 3 days for complete relief.

Find out more

No other OTC PPI lasts longer^1,2

Esomeprazole passes through the liver to the bloodstream more efficiently (with less excretion) compared to omeprazole.²

Esomeprazole provides longer acid control compared to other OTC PPIs³
More than 2 hours longer acid control than omeprazole^1,2

pH>4 for 12.7 hours with esomeprazole vs 10.5 hours with omeprazole
70% more acid blockers get to the source of acid production than omeprazole⁴

More efficient delivery of acid blockers results in reduced interpatient variability in pharmacodynamic response.⁴

Nexium Control 20mg Gastro-Resistant Tablets (Esomeprazole)

Nexium Control 7 tablet pack is an ideal trial pack with one-week supply. Nexium Control 14 tablet pack offers the same protection and offers a 2-week treatment course.

Nexium Control 20mg Gastro-Resistant Capsules (Esomeprazole)

Easy-to swallow mini capsules – 53% smaller than tablet* in a portable bottle. Complete 14-day treatment course.

*based on volume

Product Information

Product Information: Please consult the Summary of Product Characteristics for full product information. Nexium Control 20 mg gastro resistant tablets and hard capsules (esomeprazole). Indications: The short term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Dosage: The recommended dose is 20 mg esomeprazole (one tablet or capsule) per day. Tablets or capsules may need to be taken for 2-3 consecutive days to achieve symptom improvement. Maximum treatment duration: up to 2 weeks. Contraindications: Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients. Esomeprazole must not be used concomitantly with nelfinavir. Precautions: Refer to doctor if patient has: Jaundice or severe liver disease, unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena and when gastric ulcer is suspected or present, malignancy should be excluded as treatment with esomeprazole may alleviate symptoms and delay diagnosis, gastric ulcer or gastrointestinal surgery, continuous treatment of indigestion or heartburn for 4 or more weeks, or is over 55 years old with new or recently changed symptoms. Not suitable for long term use. Treatment with proton pump inhibitors (PPIs) may lead to a slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile. Consult doctor prior to have an endoscopy or urea breath test. Co administration with atazanavir is not recommended. Interactions with medicinal products metabolised through CYP2C19 should be considered. The use of esomeprazole with clopidogrel should be discouraged. Patients should not take another PPI or H2 antagonist concomitantly. PPI are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly. Side effects: Common: headache, abdominal pain, constipation, diarrhoea, flatulence, nausea/ vomiting, fundic gland polyps (benign). Uncommon: peripheral oedema, insomnia, dizziness, paraesthesia, somnolence, vertigo, dry mouth, increased liver enzymes, dermatitis, pruritus, rash urticaria. For rare, very rare and other side effects please refer to the SPC for full information. Legal category: Supply through pharmacy only. Product licence number: EU/1/13/860/001; EU/1/13/860/002; EU/1/13/860/003; EU/1/13/860/004 and EU/1/13/860/005. MAH: GlaxoSmithKline Dungarvan Limited, Knockbrack, Dungarvan, County Waterford, Ireland. Additional information is available upon request. Text prepared: June 2022.

Contains esomeprazole. Always read the label/leaflet.